Covered recipient · General Payments record
MATTHEW JAMES ZIRWAS
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$745,357.89
625 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $592,384.00 | 176 |
| Travel and Lodging | $76,728.89 | 181 |
| Consulting Fee | $65,243.14 | 29 |
| Food and Beverage | $10,763.66 | 233 |
| Education | $238.20 | 6 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $132,556.08 | 144 |
| GENZYME CORPORATION | $120,815.55 | 81 |
| Regeneron Healthcare Solutions, Inc. | $107,253.76 | 70 |
| Dermavant Sciences, Inc. | $85,521.93 | 50 |
| LEO Pharma Inc. | $73,314.00 | 68 |
| Incyte Corporation | $66,687.76 | 65 |
| Lilly USA, LLC | $56,842.78 | 49 |
| PFIZER INC. | $50,398.01 | 28 |
| Galderma Laboratories, L.P. | $19,759.33 | 18 |
| Arcutis Biotherapeutics, Inc. | $9,822.21 | 15 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $9,123.33 | 11 |
| Verrica Pharmaceuticals Inc. | $8,288.93 | 5 |
| Janssen Scientific Affairs, LLC | $2,244.50 | 4 |
| Genentech USA, Inc. | $2,220.00 | 1 |
| Janssen Biotech, Inc. | $295.65 | 10 |
| Sun Pharmaceutical Industries Inc. | $98.51 | 2 |
| Regeneron Pharmaceuticals, Inc. | $43.92 | 1 |
| Blueprint Medicines Corporation | $24.99 | 1 |
| Krystal Biotech Inc | $23.63 | 1 |
| Almirall LLC | $23.02 | 1 |
Page 5 of 13; records 201–250 of 625 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MATTHEW JAMES ZIRWAS
NPI 1699741876 · CMS profile ID 76317
Allopathic & Osteopathic Physicians / Dermatology
BEXLEY, OH
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 5 of 13; records 201–250 of 625 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1699741876?year=2023&recipient=provider&page=5#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MATTHEW JAMES ZIRWAS, NPI 1699741876, CMS profile ID 76317. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 13; records 201–250 of 625 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1699741876?year=2023&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). MATTHEW JAMES ZIRWAS, NPI 1699741876, CMS profile ID 76317. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 13; records 201–250 of 625 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1699741876?year=2023&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- MATTHEW JAMES ZIRWAS, NPI 1699741876, CMS profile ID 76317, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 13; records 201–250 of 625 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1699741876?year=2023&recipient=provider&page=5#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
625 matching records · $745,357.89 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 201–250 of 625.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Incyte Corporation | $121.13 | 08/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044491497 | CMS |
| Incyte Corporation | $1,400.00 | 08/15/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044491783 | CMS |
| Incyte Corporation | $5,600.00 | 08/15/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044491857 | CMS |
| AbbVie Inc. | $4,725.00 | 08/14/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999868781 | CMS |
| AbbVie Inc. | $96.00 | 08/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999868769 | CMS |
| AbbVie Inc. | $903.68 | 08/10/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999868773 | CMS |
| LEO Pharma Inc. | $81.44 | 08/09/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053546691 | CMS |
| LEO Pharma Inc. | $22.00 | 08/09/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053546697 | CMS |
| LEO Pharma Inc. | $7,120.00 | 08/09/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053546703 | CMS |
| AbbVie Inc. | $62.99 | 08/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999868753 | CMS |
| AbbVie Inc. | $480.07 | 08/08/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999868759 | CMS |
| Dermavant Sciences, Inc. | $1,600.00 | 08/08/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991272031 | CMS |
| Incyte Corporation | $4.25 | 08/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044491885 | CMS |
| Regeneron Healthcare Solutions, Inc. | $3,699.00 | 08/08/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999570802 | CMS |
| Regeneron Healthcare Solutions, Inc. | $3,699.00 | 08/08/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999570807 | CMS |
| Regeneron Healthcare Solutions, Inc. | $3,699.00 | 08/08/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999570815 | CMS |
| AbbVie Inc. | $8.43 | 08/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999868745 | CMS |
| Dermavant Sciences, Inc. | $126.18 | 08/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991272015 | CMS |
| Dermavant Sciences, Inc. | $496.00 | 08/07/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991272019 | CMS |
| Dermavant Sciences, Inc. | $50.04 | 08/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991272023 | CMS |
| Dermavant Sciences, Inc. | $666.30 | 08/07/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991272027 | CMS |
| Dermavant Sciences, Inc. | $1,600.00 | 08/03/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991272011 | CMS |
| Janssen Biotech, Inc. | $124.31 | 08/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988493465 | CMS |
| Regeneron Healthcare Solutions, Inc. | $3,699.00 | 08/03/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999570789 | CMS |
| Regeneron Healthcare Solutions, Inc. | $8,220.00 | 08/03/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999570795 | CMS |
| Incyte Corporation | $6,300.00 | 08/02/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044493000 | CMS |
| LEO Pharma Inc. | $118.49 | 08/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053546673 | CMS |
| LEO Pharma Inc. | $186.00 | 08/02/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053546681 | CMS |
| LEO Pharma Inc. | $629.80 | 08/02/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053546685 | CMS |
| Lilly USA, LLC | $2,400.00 | 08/02/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031840543 | CMS |
| AbbVie Inc. | $7.88 | 08/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999868737 | CMS |
| Incyte Corporation | $109.80 | 08/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044491793 | CMS |
| Incyte Corporation | $1,257.63 | 08/01/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044491867 | CMS |
| Regeneron Healthcare Solutions, Inc. | $360.33 | 08/01/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999570753 | CMS |
| Regeneron Healthcare Solutions, Inc. | $205.90 | 08/01/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999570761 | CMS |
| Regeneron Healthcare Solutions, Inc. | $514.75 | 08/01/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999570766 | CMS |
| Regeneron Healthcare Solutions, Inc. | $308.85 | 08/01/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999570775 | CMS |
| Regeneron Healthcare Solutions, Inc. | $728.90 | 08/01/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999570781 | CMS |
| Regeneron Healthcare Solutions, Inc. | $301.68 | 07/29/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999570737 | CMS |
| Regeneron Healthcare Solutions, Inc. | $38.97 | 07/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999570747 | CMS |
| Regeneron Healthcare Solutions, Inc. | $121.82 | 07/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999570731 | CMS |
| Dermavant Sciences, Inc. | $1,600.00 | 07/27/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991272007 | CMS |
| PFIZER INC. | $797.35 | 07/27/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049272575 | CMS |
| Regeneron Healthcare Solutions, Inc. | $19.13 | 07/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999570718 | CMS |
| Regeneron Healthcare Solutions, Inc. | $109.38 | 07/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999570725 | CMS |
| Regeneron Healthcare Solutions, Inc. | $17.87 | 07/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999570713 | CMS |
| AbbVie Inc. | $9.95 | 07/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999868729 | CMS |
| GENZYME CORPORATION | $25.30 | 07/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049978263 | CMS |
| Arcutis Biotherapeutics, Inc. | $750.00 | 07/21/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044794703 | CMS |
| PFIZER INC. | $3,900.00 | 07/21/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049330239 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $31,097.00 | 6 |
| PY2025 | Principal investigator | $807,992.60 | 402 |
| PY2024 | Recipient | $57,020.00 | 9 |
| PY2024 | Principal investigator | $509,094.77 | 788 |
| PY2023 | Recipient | $8,134.02 | 2 |
| PY2023 | Principal investigator | $570,650.57 | 397 |
| PY2022 | Recipient | $729.00 | 3 |
| PY2022 | Principal investigator | $401,812.93 | 108 |
| PY2021 | Recipient | $91,830.95 | 17 |
| PY2021 | Principal investigator | $608,899.39 | 53 |
| PY2020 | Recipient | $145,958.01 | 13 |
| PY2020 | Principal investigator | $356,072.29 | 79 |
| PY2019 | Recipient | $315,294.23 | 25 |
| PY2019 | Principal investigator | $850,245.17 | 76 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
408 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,420.25 | 12/17/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223289866 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,560.00 | 12/15/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175161365 |
| Principal investigator 1 | ABBVIE INC. | $16,870.30 | 12/04/2025 | Non-covered Recipient Entity DERMATOLOGISTS OF SOUTHWEST OHIO INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202526692 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500.00 | 12/03/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223289178 |
| Principal investigator 1 | Incyte Corporation | $2.12 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509536 |
| Principal investigator 1 | Incyte Corporation | $22.90 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509540 |
| Principal investigator 1 | Incyte Corporation | $1.02 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509544 |
| Principal investigator 1 | Incyte Corporation | $22.90 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509549 |
| Principal investigator 1 | Incyte Corporation | $9.48 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509572 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509577 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509581 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509585 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509589 |
| Principal investigator 1 | Incyte Corporation | $137.40 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509593 |
| Principal investigator 1 | Incyte Corporation | $7.11 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509598 |
| Principal investigator 1 | Incyte Corporation | $7.11 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509603 |
| Principal investigator 1 | Incyte Corporation | $52.14 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509607 |
| Principal investigator 1 | Incyte Corporation | $270.80 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509620 |
| Principal investigator 1 | Incyte Corporation | $1.02 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509624 |
| Principal investigator 1 | Incyte Corporation | $11.85 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509627 |
| Principal investigator 1 | Incyte Corporation | $14.22 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509631 |
| Principal investigator 1 | Incyte Corporation | $23.70 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509635 |
| Principal investigator 1 | Incyte Corporation | $10.60 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509638 |
| Principal investigator 1 | Incyte Corporation | $4.86 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509642 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509654 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509660 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509669 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509673 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509677 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509681 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509717 |
| Principal investigator 1 | Incyte Corporation | $124.54 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509729 |
| Principal investigator 1 | Incyte Corporation | $4.74 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509734 |
| Principal investigator 1 | Incyte Corporation | $54.76 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509738 |
| Principal investigator 1 | Incyte Corporation | $16.18 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509746 |
| Principal investigator 1 | Incyte Corporation | $54.51 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509754 |
| Principal investigator 1 | Incyte Corporation | $52.14 | 12/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509781 |
| Principal investigator 1 | PFIZER INC. | $5,136.75 | 11/26/2025 | Non-covered Recipient Entity Probity Medical Research Corp | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228706991 |
| Principal investigator 1 | PFIZER INC. | $2,498.96 | 11/26/2025 | Non-covered Recipient Entity Probity Medical Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228707433 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,543.82 | 11/19/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223288585 |
| Principal investigator 1 | PFIZER INC. | $12,906.68 | 11/18/2025 | Non-covered Recipient Entity Probity Medical Research Corp | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228707335 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,956.00 | 11/17/2025 | Non-covered Recipient Entity Probity Medical Research Corp | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226080262 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,714.16 | 11/12/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223288285 |
| Principal investigator 1 | ABBVIE INC. | $23,128.00 | 11/05/2025 | Non-covered Recipient Entity DERMATOLOGISTS OF SOUTHWEST OHIO INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202522427 |
| Principal investigator 1 | Incyte Corporation | $0.31 | 11/05/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509612 |
| Principal investigator 1 | Incyte Corporation | $12.15 | 11/05/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509645 |
| Principal investigator 1 | Incyte Corporation | $236.52 | 11/05/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509690 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 11/05/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509694 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 11/05/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509698 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 11/05/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509704 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 11/05/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509709 |
| Principal investigator 1 | Incyte Corporation | $24.68 | 11/05/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509713 |
| Principal investigator 1 | Incyte Corporation | $124.54 | 11/05/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509758 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 11/05/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509766 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 11/05/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509770 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 11/05/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509774 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 11/05/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509778 |
| Principal investigator 1 | Incyte Corporation | $541.60 | 11/05/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509785 |
| Principal investigator 1 | Incyte Corporation | $24.30 | 11/05/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509807 |
| Principal investigator 1 | Incyte Corporation | $2.43 | 11/05/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509810 |
| Principal investigator 1 | PFIZER INC. | $2,688.12 | 11/05/2025 | Non-covered Recipient Entity Probity Medical Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228707730 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 11/03/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509556 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 11/03/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509561 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 11/03/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509565 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 11/03/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509569 |
| Principal investigator 1 | Incyte Corporation | $12.72 | 11/03/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509649 |
| Principal investigator 1 | Incyte Corporation | $236.52 | 11/03/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509722 |
| Principal investigator 1 | Incyte Corporation | $97.08 | 11/03/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509725 |
| Principal investigator 1 | Incyte Corporation | $541.60 | 11/03/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509762 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,414.25 | 11/03/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223287923 |
| Principal investigator 1 | PFIZER INC. | $1,981.80 | 10/31/2025 | Non-covered Recipient Entity Probity Medical Research Corp | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228707163 |
| Principal investigator 1 | PFIZER INC. | $1,435.73 | 10/29/2025 | Non-covered Recipient Entity Probity Medical Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228707537 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 10/27/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175161308 |
| Principal investigator 1 | PFIZER INC. | $4,970.55 | 10/22/2025 | Non-covered Recipient Entity Probity Medical Research Corp | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228706993 |
| Principal investigator 1 | PFIZER INC. | $1,199.48 | 10/22/2025 | Non-covered Recipient Entity Probity Medical Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228707355 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,824.54 | 10/22/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223287247 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,622.42 | 10/17/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223287127 |
| Principal investigator 1 | ABBVIE INC. | $1,473.98 | 10/09/2025 | Non-covered Recipient Entity DERMATOLOGISTS OF SW OHIO LLC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202513861 |
| Principal investigator 1 | ABBVIE INC. | $10,540.58 | 10/09/2025 | Non-covered Recipient Entity DERMATOLOGISTS OF SOUTHWEST OHIO INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202516321 |
| Principal investigator 1 | PFIZER INC. | $1,320.98 | 10/04/2025 | Non-covered Recipient Entity Probity Medical Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228707533 |
| Principal investigator 1 | Incyte Corporation | $7.29 | 10/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509553 |
| Principal investigator 1 | Incyte Corporation | $98.72 | 10/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509616 |
| Principal investigator 1 | Incyte Corporation | $10.60 | 10/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509664 |
| Principal investigator 1 | Incyte Corporation | $311.35 | 10/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509686 |
| Principal investigator 1 | Incyte Corporation | $2.43 | 10/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509742 |
| Principal investigator 1 | Incyte Corporation | $1.24 | 10/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509750 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 10/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509790 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 10/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509794 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 10/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509798 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 10/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509803 |
| Principal investigator 1 | PFIZER INC. | $5,580.50 | 09/26/2025 | Non-covered Recipient Entity Probity Medical Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228707257 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,000.00 | 09/26/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285953 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,000.00 | 09/26/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285955 |
| Principal investigator 1 | PFIZER INC. | $11,742.07 | 09/24/2025 | Non-covered Recipient Entity Probity Medical Research Corp | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228707535 |
| Principal investigator 1 | PFIZER INC. | $740.30 | 09/24/2025 | Non-covered Recipient Entity Probity Medical Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228707814 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,763.44 | 09/24/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285866 |
| Principal investigator 1 | PFIZER INC. | $2,756.71 | 09/19/2025 | Non-covered Recipient Entity Probity Medical Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228707716 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,954.46 | 09/19/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223285738 |
| Principal investigator 1 | PFIZER INC. | $1,199.48 | 09/12/2025 | Non-covered Recipient Entity Probity Medical Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228707337 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,000.00 | 09/10/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223285275 |
| Principal investigator 1 | PFIZER INC. | $9,712.58 | 09/09/2025 | Non-covered Recipient Entity Probity Medical Research Corp | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228707069 |
| Principal investigator 1 | ABBVIE INC. | $26,432.75 | 09/04/2025 | Non-covered Recipient Entity DERMATOLOGISTS OF SOUTHWEST OHIO INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202509480 |
| Recipient | PFIZER INC. | $940.00 | 09/04/2025 | Covered Recipient Physician | ABROCITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727127 |
| Principal investigator 1 | ABBVIE INC. | $2,245.04 | 09/03/2025 | Non-covered Recipient Entity DERMATOLOGISTS OF SW OHIO LLC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202507903 |
| Principal investigator 1 | Incyte Corporation | $74.04 | 09/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509303 |
| Principal investigator 1 | Incyte Corporation | $16.18 | 09/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509308 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 09/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509312 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 09/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509315 |
| Principal investigator 1 | Incyte Corporation | $54.76 | 09/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509320 |
| Principal investigator 1 | Incyte Corporation | $469.45 | 09/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509324 |
| Principal investigator 1 | Incyte Corporation | $48.54 | 09/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509328 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 09/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509334 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 09/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509338 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 09/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509342 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 09/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509346 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 09/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509350 |
| Principal investigator 1 | Incyte Corporation | $8.22 | 09/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509354 |
| Principal investigator 1 | Incyte Corporation | $6.36 | 09/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509358 |
| Principal investigator 1 | Incyte Corporation | $59.13 | 09/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509362 |
| Principal investigator 1 | Incyte Corporation | $74.04 | 09/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509366 |
| Principal investigator 1 | Incyte Corporation | $135.40 | 09/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509370 |
| Principal investigator 1 | Incyte Corporation | $62.27 | 09/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509374 |
| Principal investigator 1 | Incyte Corporation | $2.12 | 09/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509378 |
| Principal investigator 1 | Incyte Corporation | $109.52 | 09/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509381 |
| Principal investigator 1 | Incyte Corporation | $12.72 | 09/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509386 |
| Principal investigator 1 | Incyte Corporation | $16.18 | 09/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509394 |
| Principal investigator 1 | Incyte Corporation | $11.45 | 09/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509410 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 09/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509450 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 09/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509453 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 09/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509457 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 09/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509461 |
| Recipient | PFIZER INC. | $3,200.00 | 08/25/2025 | Covered Recipient Physician | ABROCITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727453 |
| Principal investigator 1 | PFIZER INC. | $4,081.06 | 08/23/2025 | Non-covered Recipient Entity Probity Medical Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228707910 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,372.99 | 08/22/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223284559 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,991.02 | 08/20/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223284437 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,524.18 | 08/20/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223284439 |
| Principal investigator 1 | PFIZER INC. | $18,054.86 | 08/09/2025 | Non-covered Recipient Entity Probity Medical Research Corp | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228707071 |
| Principal investigator 1 | ABBVIE INC. | $38,040.20 | 08/06/2025 | Non-covered Recipient Entity DERMATOLOGISTS OF SOUTHWEST OHIO INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202502917 |
| Principal investigator 1 | ABBVIE INC. | $1,859.51 | 08/05/2025 | Non-covered Recipient Entity DERMATOLOGISTS OF SW OHIO LLC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202501644 |
| Principal investigator 1 | PFIZER INC. | $2,676.38 | 08/05/2025 | Non-covered Recipient Entity Probity Medical Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228707255 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 08/04/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509390 |
| Principal investigator 1 | Incyte Corporation | $57.25 | 08/04/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509397 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 08/04/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509401 |
| Principal investigator 1 | Incyte Corporation | $4.24 | 08/04/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509406 |
| Principal investigator 1 | Incyte Corporation | $54.76 | 08/04/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509415 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 08/04/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509418 |
| Principal investigator 1 | Incyte Corporation | $240.45 | 08/04/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509422 |
| Principal investigator 1 | Incyte Corporation | $29.16 | 08/04/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509426 |
| Principal investigator 1 | Incyte Corporation | $1.55 | 08/04/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509430 |
| Principal investigator 1 | Incyte Corporation | $123.40 | 08/04/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509435 |
| Principal investigator 1 | Incyte Corporation | $137.40 | 08/04/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509438 |
| Principal investigator 1 | Incyte Corporation | $80.90 | 08/04/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509442 |
| Principal investigator 1 | Incyte Corporation | $48.54 | 08/04/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509445 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 08/04/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509464 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 08/04/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509468 |
| Principal investigator 1 | PFIZER INC. | $5,778.70 | 07/29/2025 | Non-covered Recipient Entity Probity Medical Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228707435 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,235.00 | 07/28/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175161322 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,390.53 | 07/23/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223283054 |
| Principal investigator 1 | PFIZER INC. | $2,263.96 | 07/16/2025 | Non-covered Recipient Entity Probity Medical Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228707638 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,284.00 | 07/14/2025 | Non-covered Recipient Entity Probity Medical Research Corp | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226080243 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $16,000.00 | 07/11/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223282602 |
| Principal investigator 1 | ABBVIE INC. | $26,633.01 | 07/03/2025 | Non-covered Recipient Entity DERMATOLOGISTS OF SOUTHWEST OHIO INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202496813 |
| Principal investigator 1 | ABBVIE INC. | $1,473.98 | 07/02/2025 | Non-covered Recipient Entity DERMATOLOGISTS OF SW OHIO LLC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202495503 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $500.00 | 07/02/2025 | Non-covered Recipient Entity Probity Medical Research Corp | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226080247 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 07/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509264 |
| Principal investigator 1 | Incyte Corporation | $4.24 | 07/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509269 |
| Principal investigator 1 | Incyte Corporation | $186.81 | 07/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509274 |
| Principal investigator 1 | Incyte Corporation | $4.86 | 07/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509278 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 07/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509282 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 07/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509286 |
| Principal investigator 1 | Incyte Corporation | $0.62 | 07/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509291 |
| Principal investigator 1 | Incyte Corporation | $0.62 | 07/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509294 |
| Principal investigator 1 | Incyte Corporation | $54.76 | 07/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509299 |
| Principal investigator 1 | Incyte Corporation | $114.50 | 07/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509331 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 07/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509474 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 07/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509480 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 07/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509483 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 07/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509488 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 07/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509492 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 07/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509497 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 07/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509501 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 07/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509505 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 07/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509509 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 07/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509516 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 07/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509519 |
| Principal investigator 1 | Incyte Corporation | $91.60 | 07/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509524 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 07/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509528 |
| Principal investigator 1 | Incyte Corporation | $4.86 | 07/01/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509532 |
| Principal investigator 1 | PFIZER INC. | $2,881.58 | 07/01/2025 | Non-covered Recipient Entity Probity Medical Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228707718 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,910.28 | 07/01/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223282038 |
| Principal investigator 1 | PFIZER INC. | $10,020.38 | 06/26/2025 | Non-covered Recipient Entity Probity Medical Research Corp | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228708706 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,616.30 | 06/25/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223281890 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,245.00 | 06/16/2025 | Non-covered Recipient Entity Probity Medical Research Corp | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226080226 |
| Principal investigator 1 | ABBVIE INC. | $2,584.22 | 06/12/2025 | Non-covered Recipient Entity DERMATOLOGISTS OF SW OHIO LLC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202491321 |
| Principal investigator 1 | ABBVIE INC. | $364.00 | 06/10/2025 | Non-covered Recipient Entity DERMATOLOGISTS OF SW OHIO LLC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202490765 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,356.00 | 06/09/2025 | Non-covered Recipient Entity Probity Medical Research Corp | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226080222 |
| Principal investigator 1 | ABBVIE INC. | $5,898.55 | 06/03/2025 | Non-covered Recipient Entity DERMATOLOGISTS OF SOUTHWEST OHIO INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202489379 |
| Principal investigator 1 | Incyte Corporation | $17.51 | 06/03/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509148 |
| Principal investigator 1 | Incyte Corporation | $25.75 | 06/03/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509173 |
| Principal investigator 1 | PFIZER INC. | $5,105.04 | 05/29/2025 | Non-covered Recipient Entity Probity Medical Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228707640 |
| Principal investigator 1 | PFIZER INC. | $26,041.18 | 05/29/2025 | Non-covered Recipient Entity Probity Medical Research Corp | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1228707720 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,393.63 | 05/28/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223280470 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $225.00 | 05/28/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223280472 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $12,300.00 | 05/27/2025 | Non-covered Recipient Entity Probity Medical Research Corp | A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226080214 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,952.00 | 05/26/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175161289 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,250.47 | 05/21/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223280028 |
| Principal investigator 1 | PFIZER INC. | $3,902.19 | 05/15/2025 | Non-covered Recipient Entity Probity Medical Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228707732 |
| Recipient | PFIZER INC. | $330.00 | 05/08/2025 | Covered Recipient Physician | ABROCITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228759975 |
| Principal investigator 1 | ABBVIE INC. | $30,193.60 | 05/07/2025 | Non-covered Recipient Entity DERMATOLOGISTS OF SOUTHWEST OHIO INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202483163 |
| Recipient | PFIZER INC. | $330.00 | 05/07/2025 | Covered Recipient Physician | ABROCITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228760646 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,631.19 | 05/07/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223279122 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,515.00 | 05/05/2025 | Non-covered Recipient Entity Probity Medical Research Corp | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226080210 |
| Principal investigator 1 | PFIZER INC. | $8,087.04 | 05/03/2025 | Non-covered Recipient Entity Probity Medical Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228707812 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 05/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508989 |
| Principal investigator 1 | Incyte Corporation | $4.24 | 05/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509066 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 05/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509091 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 05/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509107 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 05/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509111 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 05/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509115 |
| Principal investigator 1 | Incyte Corporation | $0.62 | 05/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509119 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 05/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509122 |
| Principal investigator 1 | Incyte Corporation | $118.26 | 05/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509126 |
| Principal investigator 1 | Incyte Corporation | $9.72 | 05/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509130 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 05/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509133 |
| Principal investigator 1 | Incyte Corporation | $311.35 | 05/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509137 |
| Principal investigator 1 | Incyte Corporation | $125.95 | 05/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509141 |
| Principal investigator 1 | Incyte Corporation | $24.68 | 05/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509145 |
| Principal investigator 1 | Incyte Corporation | $34.35 | 05/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509152 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 05/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509157 |
| Principal investigator 1 | Incyte Corporation | $125.95 | 05/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509161 |
| Principal investigator 1 | Incyte Corporation | $54.76 | 05/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509184 |
| Principal investigator 1 | Incyte Corporation | $6.36 | 05/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509221 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 05/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509229 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 05/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509233 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 05/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509240 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 05/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509243 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 05/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509247 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 05/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509251 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 05/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509255 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 05/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509259 |
| Principal investigator 1 | PFIZER INC. | $6,533.19 | 05/02/2025 | Non-covered Recipient Entity Probity Medical Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228707353 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $964.65 | 05/01/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223278786 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,634.00 | 04/28/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175161336 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,025.00 | 04/28/2025 | Non-covered Recipient Entity Probity Medical Research Corp | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226080202 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $13,048.00 | 04/28/2025 | Non-covered Recipient Entity Probity Medical Research Corp | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226080206 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,815.78 | 04/11/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223277966 |
| Principal investigator 1 | PFIZER INC. | $651.25 | 04/08/2025 | Non-covered Recipient Entity Probity Medical Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228707159 |
| Principal investigator 1 | ABBVIE INC. | $22,946.55 | 04/03/2025 | Non-covered Recipient Entity DERMATOLOGISTS OF SOUTHWEST OHIO INC | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202473597 |
| Principal investigator 1 | ABBVIE INC. | $1,434.98 | 04/03/2025 | Non-covered Recipient Entity DERMATOLOGISTS OF SW OHIO LLC | A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202473601 |
| Principal investigator 1 | Arcutis Biotherapeutics, Inc. | $2,000.00 | 04/02/2025 | Non-covered Recipient Entity Bexley Derm: Dermatologists of Greater Columbus | A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Pharmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata | No dispute reported | 06/30/2026 | 1248163710 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508985 |
| Principal investigator 1 | Incyte Corporation | $24.30 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508992 |
| Principal investigator 1 | Incyte Corporation | $177.39 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508996 |
| Principal investigator 1 | Incyte Corporation | $57.25 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509000 |
| Principal investigator 1 | Incyte Corporation | $1.55 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509004 |
| Principal investigator 1 | Incyte Corporation | $80.90 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509008 |
| Principal investigator 1 | Incyte Corporation | $123.40 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509011 |
| Principal investigator 1 | Incyte Corporation | $14.58 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509015 |
| Principal investigator 1 | Incyte Corporation | $4.86 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509020 |
| Principal investigator 1 | Incyte Corporation | $0.62 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509025 |
| Principal investigator 1 | Incyte Corporation | $15.45 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509028 |
| Principal investigator 1 | Incyte Corporation | $91.60 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509032 |
| Principal investigator 1 | Incyte Corporation | $10.76 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509037 |
| Principal investigator 1 | Incyte Corporation | $26.90 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509041 |
| Principal investigator 1 | Incyte Corporation | $4.12 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509045 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509050 |
| Principal investigator 1 | Incyte Corporation | $79.50 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509054 |
| Principal investigator 1 | Incyte Corporation | $21.20 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509058 |
| Principal investigator 1 | Incyte Corporation | $32.28 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509062 |
| Principal investigator 1 | Incyte Corporation | $10.76 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509070 |
| Principal investigator 1 | Incyte Corporation | $26.90 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509074 |
| Principal investigator 1 | Incyte Corporation | $63.60 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509078 |
| Principal investigator 1 | Incyte Corporation | $95.40 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509083 |
| Principal investigator 1 | Incyte Corporation | $106.00 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509087 |
| Principal investigator 1 | Incyte Corporation | $53.00 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509095 |
| Principal investigator 1 | Incyte Corporation | $63.60 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509099 |
| Principal investigator 1 | Incyte Corporation | $116.60 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509103 |
| Principal investigator 1 | Incyte Corporation | $62.27 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509165 |
| Principal investigator 1 | Incyte Corporation | $43.04 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509169 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509179 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509187 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509194 |
| Principal investigator 1 | Incyte Corporation | $16.44 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509198 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509202 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509206 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509210 |
| Principal investigator 1 | Incyte Corporation | $41.10 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509213 |
| Principal investigator 1 | Incyte Corporation | $143.10 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509217 |
| Principal investigator 1 | Incyte Corporation | $32.28 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509224 |
| Principal investigator 1 | Incyte Corporation | $121.90 | 04/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240509235 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,669.38 | 03/26/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223277047 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,246.00 | 03/24/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175161269 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $675.00 | 03/19/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223276843 |
| Principal investigator 1 | ABBVIE INC. | $19,198.85 | 03/07/2025 | Non-covered Recipient Entity DERMATOLOGISTS OF SOUTHWEST OHIO INC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202460387 |
| Principal investigator 1 | Arcutis Biotherapeutics, Inc. | $750.00 | 03/07/2025 | Non-covered Recipient Entity Bexley Derm: Dermatologists of Greater Columbus | A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Pharmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata | No dispute reported | 06/30/2026 | 1248163708 |
| Principal investigator 1 | ABBVIE INC. | $3,641.02 | 03/06/2025 | Non-covered Recipient Entity DERMATOLOGISTS OF SW OHIO LLC | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202457330 |
| Principal investigator 1 | ABBVIE INC. | $473.20 | 03/06/2025 | Non-covered Recipient Entity DERMATOLOGISTS OF SW OHIO LLC | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202457410 |
| Principal investigator 1 | ABBVIE INC. | $1,440.00 | 03/06/2025 | Non-covered Recipient Entity DERMATOLOGISTS OF SW OHIO LLC | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202457415 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,128.00 | 03/06/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175161351 |
| Principal investigator 1 | PFIZER INC. | $4,894.96 | 03/05/2025 | Non-covered Recipient Entity Probity Medical Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228706989 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 03/03/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508809 |
| Principal investigator 1 | Incyte Corporation | $14.58 | 03/03/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508813 |
| Principal investigator 1 | Incyte Corporation | $9.72 | 03/03/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508816 |
| Principal investigator 1 | Incyte Corporation | $1.86 | 03/03/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508821 |
| Principal investigator 1 | Incyte Corporation | $57.25 | 03/03/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508824 |
| Principal investigator 1 | Incyte Corporation | $148.08 | 03/03/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508829 |
| Principal investigator 1 | Incyte Corporation | $1.24 | 03/03/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508833 |
| Principal investigator 1 | Incyte Corporation | $45.80 | 03/03/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508837 |
| Principal investigator 1 | Incyte Corporation | $148.85 | 03/03/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508841 |
| Principal investigator 1 | Incyte Corporation | $16.18 | 03/03/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508845 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 03/03/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508880 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 03/03/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508884 |
| Principal investigator 1 | Incyte Corporation | $49.32 | 03/03/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508888 |
| Principal investigator 1 | PFIZER INC. | $25,493.35 | 03/01/2025 | Non-covered Recipient Entity Probity Medical Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228707333 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,361.15 | 02/26/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223275635 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $209.25 | 02/24/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223275503 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,949.00 | 02/21/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175161328 |
| Principal investigator 1 | PFIZER INC. | $7,310.02 | 02/13/2025 | Non-covered Recipient Entity Probity Medical Research Inc | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228752545 |
| Principal investigator 1 | ABBVIE INC. | $30,885.38 | 02/12/2025 | Non-covered Recipient Entity DERMATOLOGISTS OF SOUTHWEST OHIO INC | M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1202450614 |
| Principal investigator 1 | PFIZER INC. | $41,716.41 | 02/08/2025 | Non-covered Recipient Entity Probity Medical Research Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO | No dispute reported | 06/30/2026 | 1228707161 |
| Principal investigator 1 | ABBVIE INC. | $385.53 | 02/05/2025 | Non-covered Recipient Entity DERMATOLOGISTS OF SW OHIO LLC | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202444196 |
| Principal investigator 1 | Arcutis Biotherapeutics, Inc. | $5,337.55 | 02/05/2025 | Non-covered Recipient Entity Bexley Derm: Dermatologists of Greater Columbus | A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Pharmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata | No dispute reported | 06/30/2026 | 1248163706 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,909.36 | 02/05/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223274851 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,875.00 | 02/05/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223274853 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,995.70 | 02/05/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223274855 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,776.00 | 01/27/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175161374 |
| Principal investigator 1 | Amgen Inc. | $6,749.40 | 01/21/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY RESEARCH | A Phase 3, Multicenter, Randomized, Open-label, Performance Study With Self-administered Subcutaneous Rocatinlimab (AMG 451) in Adolescent and Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Outpost) | No dispute reported | 06/30/2026 | 1246639619 |
| Principal investigator 1 | ABBVIE INC. | $3,430.01 | 01/15/2025 | Non-covered Recipient Entity DERMATOLOGISTS OF SW OHIO LLC | M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1202438629 |
| Principal investigator 1 | PFIZER INC. | $546.00 | 01/14/2025 | Non-covered Recipient Entity Probity Medical Research Inc | A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS | No dispute reported | 06/30/2026 | 1228799663 |
| Recipient | Eli Lilly and Company | $15,923.00 | 01/09/2025 | Covered Recipient Physician | AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB | No dispute reported | 06/30/2026 | 1187871887 |
| Recipient | Eli Lilly and Company | $10,374.00 | 01/09/2025 | Covered Recipient Physician | A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA | No dispute reported | 06/30/2026 | 1187871889 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,658.85 | 01/08/2025 | Non-covered Recipient Entity PROBITY MEDICAL RESEARCH CORP | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223273799 |
| Principal investigator 1 | Amgen Inc. | $19,918.33 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY RESEARCH | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246639617 |
| Principal investigator 1 | Incyte Corporation | $109.52 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508619 |
| Principal investigator 1 | Incyte Corporation | $1.24 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508623 |
| Principal investigator 1 | Incyte Corporation | $206.70 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508627 |
| Principal investigator 1 | Incyte Corporation | $196.10 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508631 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508635 |
| Principal investigator 1 | Incyte Corporation | $217.30 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508638 |
| Principal investigator 1 | Incyte Corporation | $4.86 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508642 |
| Principal investigator 1 | Incyte Corporation | $2.43 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508646 |
| Principal investigator 1 | Incyte Corporation | $68.70 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508649 |
| Principal investigator 1 | Incyte Corporation | $153.70 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508654 |
| Principal investigator 1 | Incyte Corporation | $127.20 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508658 |
| Principal investigator 1 | Incyte Corporation | $100.70 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508662 |
| Principal investigator 1 | Incyte Corporation | $100.70 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508666 |
| Principal investigator 1 | Incyte Corporation | $95.40 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508670 |
| Principal investigator 1 | Incyte Corporation | $148.40 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508674 |
| Principal investigator 1 | Incyte Corporation | $68.90 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508679 |
| Principal investigator 1 | Incyte Corporation | $90.10 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508684 |
| Principal investigator 1 | Incyte Corporation | $121.90 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508689 |
| Principal investigator 1 | Incyte Corporation | $63.60 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508693 |
| Principal investigator 1 | Incyte Corporation | $37.10 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508698 |
| Principal investigator 1 | Incyte Corporation | $42.40 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508702 |
| Principal investigator 1 | Incyte Corporation | $42.40 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508707 |
| Principal investigator 1 | Incyte Corporation | $47.70 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508711 |
| Principal investigator 1 | Incyte Corporation | $53.00 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508715 |
| Principal investigator 1 | Incyte Corporation | $31.80 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508719 |
| Principal investigator 1 | Incyte Corporation | $26.90 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508724 |
| Principal investigator 1 | Incyte Corporation | $37.10 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508727 |
| Principal investigator 1 | Incyte Corporation | $21.52 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508732 |
| Principal investigator 1 | Incyte Corporation | $32.28 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508736 |
| Principal investigator 1 | Incyte Corporation | $32.28 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508741 |
| Principal investigator 1 | Incyte Corporation | $21.20 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508746 |
| Principal investigator 1 | Incyte Corporation | $10.76 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508750 |
| Principal investigator 1 | Incyte Corporation | $21.52 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508754 |
| Principal investigator 1 | Incyte Corporation | $21.52 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508756 |
| Principal investigator 1 | Incyte Corporation | $21.52 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508759 |
| Principal investigator 1 | Incyte Corporation | $57.25 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508763 |
| Principal investigator 1 | Incyte Corporation | $16.14 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508767 |
| Principal investigator 1 | Incyte Corporation | $16.14 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508771 |
| Principal investigator 1 | Incyte Corporation | $10.60 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508775 |
| Principal investigator 1 | Incyte Corporation | $6.18 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508779 |
| Principal investigator 1 | Incyte Corporation | $5.38 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508783 |
| Principal investigator 1 | Incyte Corporation | $32.36 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508788 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508792 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508794 |
| Principal investigator 1 | Incyte Corporation | $22.90 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508798 |
| Principal investigator 1 | Incyte Corporation | $103.05 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508804 |
| Principal investigator 1 | Incyte Corporation | $48.42 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508848 |
| Principal investigator 1 | Incyte Corporation | $49.36 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508852 |
| Principal investigator 1 | Incyte Corporation | $63.60 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508856 |
| Principal investigator 1 | Incyte Corporation | $63.60 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508860 |
| Principal investigator 1 | Incyte Corporation | $63.60 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508863 |
| Principal investigator 1 | Incyte Corporation | $498.16 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508867 |
| Principal investigator 1 | Incyte Corporation | $10.60 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508871 |
| Principal investigator 1 | Incyte Corporation | $37.66 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508875 |
| Principal investigator 1 | Incyte Corporation | $21.20 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508895 |
| Principal investigator 1 | Incyte Corporation | $31.80 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508897 |
| Principal investigator 1 | Incyte Corporation | $26.90 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508902 |
| Principal investigator 1 | Incyte Corporation | $26.90 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508906 |
| Principal investigator 1 | Incyte Corporation | $26.90 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508910 |
| Principal investigator 1 | Incyte Corporation | $26.90 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508916 |
| Principal investigator 1 | Incyte Corporation | $26.90 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508920 |
| Principal investigator 1 | Incyte Corporation | $58.30 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508924 |
| Principal investigator 1 | Incyte Corporation | $37.10 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508928 |
| Principal investigator 1 | Incyte Corporation | $42.40 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508933 |
| Principal investigator 1 | Incyte Corporation | $42.40 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508938 |
| Principal investigator 1 | Incyte Corporation | $42.40 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508943 |
| Principal investigator 1 | Incyte Corporation | $42.40 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508947 |
| Principal investigator 1 | Incyte Corporation | $59.13 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508951 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508955 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508961 |
| Principal investigator 1 | Incyte Corporation | $2.06 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508965 |
| Principal investigator 1 | Incyte Corporation | $10.76 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508969 |
| Principal investigator 1 | Incyte Corporation | $10.76 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508973 |
| Principal investigator 1 | Incyte Corporation | $21.52 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508977 |
| Principal investigator 1 | Incyte Corporation | $90.10 | 01/02/2025 | Non-covered Recipient Entity BEXLEY DERMATOLOGY | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240508982 |